The impact of long-term antiseizure treatment on cognitive decline in late-onset epileptic prodromal Alzheimer's disease: an exploratory study.
Background: The well-documented bidirectional relationship between Alzheimer's disease (AD) and epilepsy suggests that seizures are not merely a complication of AD but may also contribute to disease progression. Emerging evidence indicates that antiseizure medications (ASMs) could potentially slow t...
| Publicado en: | Frontiers in Aging Neuroscience pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Frontiers Media S.A.
2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195995281&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195995281 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16634365 BG2U jtl: Frontiers in Aging Neuroscience issn: 16634365 maglogo: N pubinfo: dt: 2026 pid: 40038 pub: Frontiers Media S.A. artinfo: ui: 195995281 195995281 195995281 10.3389/fnagi.2026.1786247 195995281 ppf: 1 ppct: 11 formats: tig: atl: The impact of long-term antiseizure treatment on cognitive decline in late-onset epileptic prodromal Alzheimer's disease: an exploratory study. aug: au: Cretin, Benjamin Philippi, Nathalie Bousiges, Olivier Dibitonto, Laure Blanc, Frederic affil: Unité de Neuropsychologie, Service de Neurologie et Hôpital de Jour de Gériatrie, Pôle de Gériatrie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France sug: subj: Alzheimer's Disease Drug Therapy Epilepsy Drug Therapy Anticonvulsants Therapeutic Use Cognition Drug Effects Long Term Care Treatment Outcomes Human Male Female Aged Retrospective Design Record Review Prospective Studies Exploratory Research Scales Cognition Disorders Prevention and Control Activities of Daily Living Matched-Pair Analysis Cox Proportional Hazards Model Electroencephalography Magnetic Resonance Imaging France Data Analysis Software Power Analysis Descriptive Statistics Chi Square Test T-Tests Univariate Statistics Multiple Regression Kaplan-Meier Estimator Log-Rank Test P-Value Post Hoc Analysis Aged: 65+ years Male Female ab: Background: The well-documented bidirectional relationship between Alzheimer's disease (AD) and epilepsy suggests that seizures are not merely a complication of AD but may also contribute to disease progression. Emerging evidence indicates that antiseizure medications (ASMs) could potentially slow the disease course and act as disease-modifying agents if initiated early. Objectives: We investigated the long-term cognitive and functional effects of ASMs when introduced at the prodromal stage of AD. Methods: Twenty-two sporadic epileptic prodromal AD patients (epADs) and 21 matched subjects without epilepsy (nepADs) were followed for a median of 7 years. Baseline cognition, daily functioning, clinical/paraclinical features, and pharmacological profiles were compared. Annual assessments included cognition, pharmacological burden, and functional impairment. Results: At the final follow-up, epADs evidenced more preserved cognition than nepADs, reflecting a significantly slower annual rate of cognitive decline (−1.2 ± 0.9 vs. −2.7 ± 2.4 points/year on the MMSE score, respectively; p = 0.01). They were also less likely to require neuroleptics (9.1% vs. 47.6%, p < 0.01) or memantine (0% vs. 28.6%, p < 0.01). However, epADs and nepADs had the same proportion of Alzheimer's dementia at the final follow-up visit (90.9% vs. 90.5%, p = 0.96). Despite being significant, these results had low statistical power due to our small sample size and should be considered exploratory. Conclusion: Our findings support the idea that early ASM treatment may attenuate cognitive decline in sporadic prodromal AD patients with comorbid epilepsy. However, these benefits were not accompanied by a lower dementia rate at the final follow-up visit, suggesting that ASMs alone are insufficient for sustained disease modification. Combinatorial therapeutic strategies may be needed to achieve long-term neuroprotection in AD. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|